To be informed of our future events and receive our meeting reports.Join Us
PrimaDiag is a French company developing and commercializing compact robotic platforms for the rapid automation of a wide variety of protocols in the field of molecular biology and genomics.
Diavein is a start-up developing and marketing an electro-stimulation device of the vascular system. Diavein aims to relieve the sickle cell disease, the most common orphan genetic disease in the world (5 million people affected). It is characterized in particular by vaso-occlusive crises, due to obstructions of the blood vessels, very painful and too often fatal.
Presentation by the management of DEINOVE, a biotechnology company discovering, developing and producing compounds from the microbial world that are of interest to the health, nutrition and cosmetics industries.
It focuses on two major families of molecules: antibiotics and carotenoids (antioxidants) and collaborates in parallel with industrial groups seeking innovation.
Presentation by the managemet of NH TherAguix,a pharmaceutical company developing innovative nanomedicine that improves the effectiveness of radiotherapy and reduces side effects without changing clinical practice. Its AGuIX® drug, in clinical phase 1, is a non-invasive, personalized solution that improves cancer imaging and treatment
Accounts of meetings with industry leaders and specialists, interviews, webinars, training modules, on-line access to company data, publications, for:
• Follow innovations in health and life sciences (Biotech, Medtech, Diagnostics, E-health, Big Data, Cleantech, Silver Economy).
• Understand the specificities of the sector
• Understand the positioning and potential of companies
Private meetings with leaders and those who make the news in biotechs.
Networking: Leaders, professionals in the healthcare industry, health professionals, researchers, institutions, consultants, fundraisers, business angels, family offices, fund managers, venture capitalists , …
Biotech Agora successfully resumed the concept of privileged encounters between individual investors passionate about the health sector and leaders of biotechnology companies. Participants are of high quality and aware of the innovations of the different actors. The formula combines conviviality and personalized relationships in an exclusive setting. In summary, a very good springboard to become better acquainted with individual shareholders particularly active in our field.
I very much appreciated the meeting organized by Biotech Agora and the discussions with the people present at the event.
The format, format and quality of the assistance lent itself very well to presentation and discussion.
This type of meeting has a very positive and pedagogical impact: it helps to maintain a link with investors who are very demanding in order to better understand the achievements and prospects of the company. It was also an opportunity to meet new investors who were not familiar with Cerenis and who were passionate about the subject.
Biotech Agora helps to disseminate objective information. This is important in the current context where a lot of misinformation can easily circulate on networks and forums to maintain a direct link with individual investors.
The format of Biotech Agora evenings with a one and a half hour conference followed by a cocktail to continue the discussions in a more informal setting is very appropriate to better understand and deepen the complex subjects.
Too often the topics are overflown and potential shareholders and investors do not always find the answers to their questions.
The presentation made by the company's CEO provides a better understanding of the project's stakes, its strengths in relation to competition, and the various phases of development in which the project fits.
The assistance of investors is enriched by the presence of biotech specialists (analysts, journalists ...) who bring a pedagogical, didactic side and raise the debates. The accessibility and the quality of the exchanges are made possible by the assistance limited to about sixty people.
I attended the Biotech Agora Cerenis evening. The presentation was brilliant, with no double talk. No false pretenses. Very good evening. To renew. Do not change anything to the setting of it.
These meetings of leaders in small committees are for me a privileged place of exchange outside the Shareholers’meetings. It also allows me to discover new and beautiful companies to which I would not necessarily have thought and appreciate their potential.
Contacts with other investors also allow to share points of view outside the forums that I do not frequent, and this, for their lack of reliability.